MDWD News and Press, MediWound Ltd. From 07/07/22

Israeli biopharma MediWound ( NASDAQ: MDWD ) climbed ~13% in the pre-market Thursday after the company announced positive data from a Phase 2 trial designed to evaluate its wound candidate EscharEx as a therapy for the debridement of lower leg ulcers. The U.S.-based op...

EscharEx Showed Safe, Effective and Rapid Debridement in VLUs and DFUs Data Demonstrate s EscharEx Reduce d Wound Size, Biofilm and Bacterial Burden YAVNE, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the ...

YAVNE, Israel, July 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it will host an in-person key opinion leader (KOL) event ...

Tzvi Palash has been appointed as COO at biopharmaceutical company MediWound ( NASDAQ: MDWD ). Palash brings over 35 years of experience, having previously served at Enlivex, where he led the design and construction of the new cGMP manufacturing facility. At MediWound,...

YAVNE, Israel, June 30, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the appointment of Mr. Tzvi Palash as Chief Operating Officer ...

MediWound Ltd. (MDWD) Q1 2022 Earnings Conference Call May 17, 2022 08:30 A.M. ET Company Participants Monique Kosse - IR Sharon Malka - CEO Boaz Gur-Lavie - Chief Financial Officer Ofer Gonen - Board Member Lior Rosenberg - Chief Medical Officer Cyaandi R. Dove - Investigator, Advanced Wound...

MediWound (NASDAQ:MDWD) appointed Ofer Gonen as CEO, effective June 30, 2022, succeeding Sharon Malka, who will join the company board. Ofer Gonen has been a board member in MediWound and the CEO of Clal Biotechnology Industries, MediWound's largest sharehol...

MediWound press release (NASDAQ:MDWD): Q1 GAAP EPS of -$0.12 misses by $0.01. Revenue of $4.4M (-24.8% Y/Y) beats by $0.11M. Shares -3.17% PM. For further details see: MediWound GAAP EPS of -$0.12 misses by $0.01, revenue of $4.4M beats by $0.11M

Ofer Gonen, current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30 Will replace current CEO Sharon Malka, who will join the Board of Directors YAVNE, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasda...

Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds On track for NexoBrid BLA resubmission by mid-year Conference C all B egins T oday at 8:30 am ET YAVNE, Israel, May 17, 2022 (GLOBE NE...